BAKER BIOTECH CAPITAL II GP LLC 4

Accession 0001181431-05-013830

CIK 0000946840other

Filed

Mar 1, 7:00 PM ET

Accepted

Mar 2, 4:53 PM ET

Size

14.3 KB

Accession

0001181431-05-013830

Form 4

Period: 2005-02-28

10% Owner

Transactions

Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-03-01+137,000→ 3,879,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (54,800 underlying)
Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-03-02+303,000→ 4,182,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (121,200 underlying)
Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-02-28+344,000→ 3,742,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (137,600 underlying)

10% Owner

Transactions

Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-02-28+344,000→ 3,742,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (137,600 underlying)
Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-03-02+303,000→ 4,182,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (121,200 underlying)
Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-03-01+137,000→ 3,879,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (54,800 underlying)

10% Owner

Transactions

Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-02-28+344,000→ 3,742,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (137,600 underlying)
Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-03-01+137,000→ 3,879,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (54,800 underlying)
Purchase
6.0% Convertible Senior Secured Notes due 2009
2005-03-02+303,000→ 4,182,000 total(indirect: See Footnote)
Exercise: $2.50Exp: 2009-10-18→ Common Stock (121,200 underlying)

Footnotes (6)

[F1]In addition to Baker Biotech Capital II (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Biotech Capital II (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were members of a group with such security holders. However, the Reporting Persons disclaim that they and any other person or persons in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
[F2]Immediately.
[F3]110% of the principal amount.
[F4]Represents notes owned directly by Baker Biotech Fund II, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital II, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital II (GP), LLC. Felix J. Baker and Julian C. Baker are the controlling members of Baker Biotech Capital II (GP), LLC.
[F5]115% of the principal amount.
[F6]121% of the principal amount.

Documents

1 file

VIROPHARMA INC

CIK 0000946840

Entity typeother

IncorporatedDE